-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, with the continuous optimization of epidemic prevention and control policies, coupled with the impact of winter influenza, the public's demand for epidemic prevention drugs has increased greatly, and physical pharmacies and online pharmacies have sold cold and cough medicines, and ibuprofen is even more "difficult to find a pill (bottle)"
.
Ibuprofen is a nonsteroidal anti-inflammatory and antirheumatic drug that can be used to relieve mild to moderate pain and high fever
caused by colds.
According to data from Minai.
com, the market scale of anti-inflammatory and anti-rheumatic drugs in retail pharmacy terminals has continued to rise in recent years, and the total sales of physical pharmacy terminals and online pharmacy terminals in China's cities have exceeded 4.
2 billion yuan
in 2021.
Physical pharmacies exceeded 4 billion! Ibuprofen held the "sales crown", and Jiangsu pharmaceutical companies rose 98%
In the six major markets of the three major terminals, the overall scale of anti-inflammatory and anti-rheumatic drugs has already exceeded 10 billion yuan, in recent years, affected by centralized procurement and price reduction, the sales scale of anti-inflammatory and anti-rheumatic drugs in public hospital terminals (urban public hospitals + county-level public hospitals) and public primary medical terminals (urban community centers + township health centers) has continued to decline, while the sales of retail pharmacy terminals (urban physical pharmacies + online pharmacies) have continued to rise
。 According to the latest data from Minai.
com, it is expected that the market size of anti-inflammatory and anti-rheumatic drugs in China's urban physical pharmacies will exceed 4 billion yuan
for the first time in 2022.
Figure 1: Sales scale of anti-inflammatory and anti-rheumatic drugs in physical pharmacies in Chinese cities (100 million yuan)
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
Table 1: Top 10 varieties of anti-inflammatory and anti-rheumatic drugs in terminal in Chinese urban physical pharmacies in 2022
Note: Sales below 100 million yuan are indicated by *
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
In 2022, it is expected that the sales of the top 6 varieties of anti-inflammatory and anti-rheumatic drugs will exceed 100 million yuan, ranking consistent
with 2021.
The ranking of Ellamod is expected to rise one place this year, with sales of more than
85 million yuan.
Ibuprofen continues to hold the top 1 variety throne, and its sales are expected to exceed 1.
4 billion yuan
in 2022.
From the perspective of drug routes, internal products accounted for more than 98%, while external products accounted for a small proportion but the sales decline was serious, dragging down the overall sales
of this variety.
Glucosamine is expected to become the new 1 billion varieties of anti-inflammatory and anti-rheumatic drugs in 2022, which can relieve and eliminate symptoms such as pain and swelling of osteoarthritis, improve joint mobility and prevent the development of
osteoarthritis.
Glucosamine is mainly an internal product, with a sales growth rate of 14.
94% in 2021 and is expected to grow as high as 22.
74%
in 2022.
In addition, diclofenac sodium and etoricoxib have maintained a growth of more than 10% in China's urban physical pharmacy terminals for two consecutive years, and the potential cannot be underestimated
.
Diclofenac sodium is indicated for relieving joint swelling and pain symptoms of arthritis, as well as for trauma, postoperative inflammation and swelling, and for fever in adults and children
.
From the perspective of drug route, internal products account for more than 99%.
The sales growth rate of diclofenac sodium in 2021 is 12.
21%, and the growth rate is expected to be as high as 16.
22% in 2022, and the sales have exceeded 600 million yuan
.
Due to the same antipyretic effect, many citizens turned to buying diclofenac sodium when they could not grab ibuprofen, which is expected to further stimulate the sales of
this variety in physical pharmacies.
Relying on coxib to relieve pain caused by osteoarthritis, it is a new variety
with sales of more than 100 million yuan in 2022.
Relying on Coxi mainly as an internal product, the sales growth rate in 2021 is 20.
52%, and the growth rate is expected to be as high as 16.
23%
in 2022.
Table 2: Top 10 brands of anti-inflammatory and anti-rheumatic drugs in the terminal of physical pharmacies in China in 2022
Note: Sales below 100 million yuan are indicated by *
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
In 2022, it is expected that the sales of the TOP9 brands of anti-inflammatory and anti-rheumatic drugs will exceed 100 million yuan, and all domestic brands will maintain a positive growth trend
.
Johnson & Johnson's ibuprofen suspension and Tianjin SmithKline Pharmaceutical's ibuprofen sustained-release capsules have been seizing the market highland, and sales are expected to exceed 400 million yuan
in 2022.
The two major brands have exceeded the 500 million yuan mark in 2019, and we will wait and see whether they will usher in a new wave of
peaks.
Jiangsu Chia Tai Qingjiang Pharmaceutical's glucosamine hydrochloride tablets are expected to increase sales by 98.
75% in 2022, rising three places
in the ranking.
The brand has exceeded 100 million yuan in 2018, and its sales fell slightly in 2020 due to the impact of the epidemic, and then returned to positive growth, and if this trend is maintained, it is expected to exceed 200 million yuan
in 2023.
Online pharmacies are growing rapidly! The three major varieties soared by 100%, and the TOP1 brand changed owners
In recent years, with the continuous promotion of online sales of prescription drugs, the overall scale of China's online pharmacy terminals is in a stage of rapid growth
.
The market size of anti-inflammatory and anti-rheumatic drugs reached 420 million yuan in 2021, and the latest data shows that the growth rate in the first half of 2022 continued to exceed 50%, and the market size has exceeded 290 million yuan
。
Figure 2: Sales scale of anti-inflammatory and anti-rheumatic drugs in Chinese online pharmacies (100 million yuan)
Source: Minai.
com China's online pharmacy drug terminal competition pattern
Table 3: Top 10 varieties of terminal anti-inflammatory and anti-rheumatic drugs in China's online pharmacies in the first half of 2022
Note: Sales below 10 million yuan are indicated by *
Source: Minai.
com China's online pharmacy drug terminal competition pattern
In the first half of 2022, in China's online pharmacy terminal, the sales of anti-inflammatory and anti-rheumatic drug TOP7 varieties exceeded 10 million yuan, of which glucosamine, ibuprofen and diclofenac sodium three varieties of growth rate of more than 100%, from the ranking point of view, ibuprofen rose 2 places, diclofenac sodium also rose 1 place
。
Figure 3: Sales of ibuprofen in the online pharmacy terminal anti-inflammatory and antirheumatic drug market (: million yuan)
Source: Minai.
com China's online pharmacy drug terminal competition pattern
In China's online pharmacy terminal anti-inflammatory and anti-rheumatic drug market, ibuprofen's sales in 2019 were only at the level of 10 million yuan, and the sales growth rate in recent years was amazing, and the sales in the first half of 2022 rose to more than 64 million yuan, becoming a TOP2 variety
.
This variety of internal products accounted for the largest proportion, external products accounted for less than 1%, in the first half of this year internal and external ibuprofen soared by more than 100%, the results are gratifying
。
Table 4: Top 10 brands of anti-inflammatory and anti-rheumatic drugs in China's online pharmacies in the first half of 2022
Note: Sales below 10 million yuan are indicated by *
Source: Minai.
com China's online pharmacy drug terminal competition pattern
In the first half of 2022, the sales of the TOP7 brands of anti-inflammatory and anti-rheumatic drugs exceeded 10 million yuan, of which Johnson & Johnson's ibuprofen suspension, Ausmei Pharmaceutical's glucosamine hydrochloride capsules and Sino-US Tianjin SmithKline's ibuprofen sustained-release capsules all had triple-digit
growth rates.
From 2019 to 2021, the TOP1 brand is Hainan Simcere Pharmaceutical's Eramod tablets, and the peak sales of this brand is 70 million yuan
in 2021.
Johnson & Johnson's ibuprofen suspension grew by 280%, 140% and 344% in the first half of 2019-2022, respectively, and successfully surpassed Hainan Simcere Pharmaceutical's Eramod tablets to become the new TOP1 brand
of anti-inflammatory and anti-rheumatic drugs in the first half of 2022.
CR Sanjiu, human happiness, sentient beings.
.
.
14 new products entered the market to grab food
The market size of anti-inflammatory and anti-rheumatic drugs in retail pharmacies continues to rise, attracting more and more companies to rush into the market
.
According to data from Minai.
com, 14 new anti-inflammatory and anti-rheumatic drugs (by product + enterprise statistics) have been approved for marketing
since the beginning of this year.
Table 5: New anti-inflammatory and anti-rheumatic drugs approved for marketing since 2022
Source: Minai.
com China Declaration Progress (MED) data
Ibuprofen is currently a hot variety in the anti-inflammatory and anti-rheumatic drug market, and ibuprofen suspension, ibuprofen softgels and arginine ibuprofen granules are welcoming new companies this year
.
CR Sanjiu has been approved for ibuprofen tablets, arginine ibuprofen powder, arginine ibuprofen granules earlier, and won the ibuprofen suspension this year, adding another heavy member
to the company's ibuprofen product matrix.
Renfu Pharmaceutical has already obtained the production approval of ibuprofen tablets and ibuprofen suspension, and this year added ibuprofen softgels
.
It is reported that in the future, the peak of the epidemic will be successively ushered in throughout the country, ibuprofen is expected to be hot for a while, if the production enterprises can seize the opportunity, while doing a good job in supply, it is also the best time to promote the brand, a new round of market reshuffle has begun
.
Source: Minainet database
Note: Minai.
com "The Competition Pattern of Drug Terminal in China's Urban Physical Pharmacies", the statistical scope is: the national prefecture-level and above citiesphysical pharmacies, excluding county and rural pharmacies; The above sales are calculated
based on the average retail price of the product at the terminal.
Minai.
com's "Competition Pattern of China's Online Pharmacy Terminals", the statistical scope is: all drug data of online pharmacies nationwide, including all online pharmacy drug data on third-party platforms such as Tmall and Jingdong and private domain platforms; The above sales are calculated based on the average retail price of the product at the online pharmacy
.
Data statistics as of December 29, if there are any omissions, welcome to correct.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). 
![benzyl N-{2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl}carbamate](https://file.echemi.com/fileManage/upload/goodpicture/20210823/m20210823171124543.jpg)
